MX2019005675A - Profarmacos hepaticos de ionoforos de protones mitocondriales. - Google Patents

Profarmacos hepaticos de ionoforos de protones mitocondriales.

Info

Publication number
MX2019005675A
MX2019005675A MX2019005675A MX2019005675A MX2019005675A MX 2019005675 A MX2019005675 A MX 2019005675A MX 2019005675 A MX2019005675 A MX 2019005675A MX 2019005675 A MX2019005675 A MX 2019005675A MX 2019005675 A MX2019005675 A MX 2019005675A
Authority
MX
Mexico
Prior art keywords
prodrugs
liver
mitochondrial proton
ionophores
proton ionophores
Prior art date
Application number
MX2019005675A
Other languages
English (en)
Inventor
James Moss Steven
Alan Gregory Matthew
Joakim Hansson Magnus
Elmér Eskil
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2019005675A publication Critical patent/MX2019005675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2433—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
    • C07F9/2441—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1) containing the structure N-P(=X)n-X-C(=X) (X = O, S, Se; n = 0, 1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/247—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2479—Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1)
    • C07F9/2487—Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1) containing the structure P(=X)n-N-C(=X) (X = O, S, Se; n = 0, 1)

Abstract

La presente invención proporciona nuevos profármacos dirigidos al hígado de ionóforos de protones mitocondriales. Estos compuestos tienen utilidad en medicina, incluido su uso en el tratamiento de enfermedades tales como la NASH y la NAFLD.
MX2019005675A 2016-11-18 2017-11-17 Profarmacos hepaticos de ionoforos de protones mitocondriales. MX2019005675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201670919 2016-11-18
PCT/EP2017/079548 WO2018091633A1 (en) 2016-11-18 2017-11-17 Liver prodrugs of mitochondrial proton ionophores

Publications (1)

Publication Number Publication Date
MX2019005675A true MX2019005675A (es) 2019-08-14

Family

ID=57460295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005675A MX2019005675A (es) 2016-11-18 2017-11-17 Profarmacos hepaticos de ionoforos de protones mitocondriales.

Country Status (11)

Country Link
US (1) US20190276481A1 (es)
EP (1) EP3541824A1 (es)
JP (1) JP2020500853A (es)
KR (1) KR20190085976A (es)
CN (1) CN110198947A (es)
AU (1) AU2017361855A1 (es)
BR (1) BR112019009988A2 (es)
CA (1) CA3043437A1 (es)
MA (1) MA46839A (es)
MX (1) MX2019005675A (es)
WO (1) WO2018091633A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610292B (zh) * 2018-06-12 2020-11-10 清华大学 一类3,5-二取代乙内酰脲类化合物及其制备方法与应用
CN111646936A (zh) * 2020-06-22 2020-09-11 江苏亚虹医药科技有限公司 芳香醚类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL59151C (es) 1945-08-22
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SG184323A1 (en) * 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
JP5937073B2 (ja) * 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
WO2015031598A2 (en) 2013-08-30 2015-03-05 Yale University Therapeutic dnp derivatives and methods using same
US9828409B2 (en) * 2014-03-19 2017-11-28 Minghong Zhong Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
CN111269264A (zh) * 2014-08-25 2020-06-12 美迪维尔公司 用于治疗癌症的尿苷的二氧戊环类似物
TWI687432B (zh) * 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療

Also Published As

Publication number Publication date
JP2020500853A (ja) 2020-01-16
EP3541824A1 (en) 2019-09-25
CN110198947A (zh) 2019-09-03
BR112019009988A2 (pt) 2019-08-27
AU2017361855A1 (en) 2019-05-30
CA3043437A1 (en) 2018-05-24
MA46839A (fr) 2021-03-24
US20190276481A1 (en) 2019-09-12
KR20190085976A (ko) 2019-07-19
WO2018091633A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
PH12016501978A1 (en) Treatment of nafld and nash
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MX2018013141A (es) Neurotoxinas quimericas.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015502161A1 (en) Therapeutic compounds and compositions
TW201613901A (en) New compounds
MX2017001279A (es) Usos y composiciones de la flagelina.
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
AU367237S (en) Inhaler
PH12018501443A1 (en) Methods of administering hepcidin
AU356657S (en) Inhaler
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2019005675A (es) Profarmacos hepaticos de ionoforos de protones mitocondriales.
AU356658S (en) Inhaler
PH12016501838A1 (en) Compounds and their methods of use
MX371538B (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
PH12019501358A1 (en) Methods of administering hepcidin
AU356644S (en) Inhaler
MY182809A (en) Compositions for the treatment of kidney and/or liver disease